000165450 001__ 165450 000165450 005__ 20260108143204.0 000165450 0248_ $$2sideral$$a147049 000165450 037__ $$aART-2017-147049 000165450 041__ $$aeng 000165450 100__ $$0(orcid)0000-0001-9243-0339$$aOlivera Pueyo, Francisco Javier$$uUniversidad de Zaragoza 000165450 245__ $$aDietary supplements for cognitive impairment 000165450 260__ $$c2017 000165450 5060_ $$aAccess copy available to the general public$$fUnrestricted 000165450 5203_ $$aAlzheimer disease and the other neurodegenerative dementias as yet have no curative treatment. For this reason, the prevention of these conditions and non-pharmacological treatments are important fields of research at present. The Mediterranean diet (rich in fruits, vegetables, legumes, and olive oil, with regular fish consumption and low consumption of dairy products and meats) has been shown to reduce the incidence of mild cognitive impairment (MCI) and, probably, the conversion of MCI to dementia. Vitamins, especially vitamin E and the vitamins of the B group, have also been associated with the prevention of cognitive impairment due to their antioxidant effects. Ginkgo biloba is one of the most widely used supplements in the world for cognitive improvement because of its possible effects as a vasodilator and facilitator of cerebral vascularization. Green tea polyphenols have shown beneficial effects in different diseases, including cognitive impairment. Cerebral aging is associated with changes in the lipid composition of neuronal membranes, so it has been suggested that treatment with phospholipids like phosphatidylcholine and phosphatidylserine could favor cognitive improvement. Similarly, polyunsaturated and omega-3 fatty acids, and docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) supplements are associated with a beneficial effect on cognitive function due to the cumulative summation of factors that ultimately favor membrane permeability and neuronal functioning. Issue Vol. 45 No. Suppl. 1 (2017) Section Original 000165450 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es 000165450 590__ $$a0.878$$b2017 000165450 591__ $$aPSYCHIATRY$$b123 / 141 = 0.872$$c2017$$dQ4$$eT3 000165450 591__ $$aNEUROSCIENCES$$b243 / 261 = 0.931$$c2017$$dQ4$$eT3 000165450 592__ $$a0.333$$b2017 000165450 593__ $$aPsychiatry and Mental Health$$c2017$$dQ3 000165450 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000165450 700__ $$0(orcid)0000-0002-4036-4541$$aPelegrín Valero, Carmelo$$uUniversidad de Zaragoza 000165450 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría 000165450 773__ $$g45, Suppl. 1 (2017), 37 - 47$$pActas esp. psiquiatr.$$tActas españolas de psiquiatría$$x1139-9287 000165450 8564_ $$s88705$$uhttps://zaguan.unizar.es/record/165450/files/texto_completo.pdf$$yVersión publicada 000165450 8564_ $$s2113596$$uhttps://zaguan.unizar.es/record/165450/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000165450 909CO $$ooai:zaguan.unizar.es:165450$$particulos$$pdriver 000165450 951__ $$a2026-01-08-14:10:50 000165450 980__ $$aARTICLE